Remikiren

Remikiren

Clinical data
ATC code	C09XA01 (WHO)
Pharmacokinetic data
Protein binding	83%
Identifiers
IUPAC name (2R)-2-(tert-butylsulfonylmethyl)-N-[(2S)-1- {[(2R,3S,4R)-1-cyclohexyl-4-cyclopropyl-3,4- dihydroxybutan-2-yl]amino}-3-(3H-imidazol- 4-yl)-1-oxopropan-2-yl]-3-phenylpropanamide
CAS Number	126222-34-2
PubChem CID	5462340
DrugBank	APRD00163
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C33H50N4O6S
Molar mass	630.839 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Remikiren is a renin inhibitor under development for the treatment of hypertension (high blood pressure). It was first developed by Hoffmann–La Roche in 1996.

References

Template:Agents acting on the renin-angiotensin system

Template:WikiDoc Sources